Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/79395
Title: Targeting the cell stress response of plasmodium falciparum to overcome artemisinin resistance
Authors: Dogovski, Con
Xie, Stanley C.
Burgio, Gaetan
Bridgford, Jess
Mok, Sachel
McCaw, James M.
Chotivanich, Kesinee
Kenny, Shannon
Gnädig, Nina
Straimer, Judith
Bozdech, Zbynek
Fidock, David A.
Simpson, Julie A.
Dondorp, Arjen M.
Foote, Simon
Klonis, Nectarios
Tilley, Leann
Keywords: DRNTU::Science::Biological sciences
Issue Date: 2015
Source: Dogovski, C., Xie, S. C., Burgio, G., Bridgford, J., Mok, S., McCaw, J. M., et al. (2015). Targeting the cell stress response of plasmodium falciparum to overcome artemisinin resistance. PLOS biology, 13(4), e1002132-.
Series/Report no.: PLOS biology
Abstract: Successful control of falciparum malaria depends greatly on treatment with artemisinin combination therapies. Thus, reports that resistance to artemisinins (ARTs) has emerged, and that the prevalence of this resistance is increasing, are alarming. ART resistance has recently been linked to mutations in the K13 propeller protein. We undertook a detailed kinetic analysis of the drug responses of K13 wild-type and mutant isolates of Plasmodium falciparum sourced from a region in Cambodia (Pailin). We demonstrate that ART treatment induces growth retardation and an accumulation of ubiquitinated proteins, indicative of a cellular stress response that engages the ubiquitin/proteasome system. We show that resistant parasites exhibit lower levels of ubiquitinated proteins and delayed onset of cell death, indicating an enhanced cell stress response. We found that the stress response can be targeted by inhibiting the proteasome. Accordingly, clinically used proteasome inhibitors strongly synergize ART activity against both sensitive and resistant parasites, including isogenic lines expressing mutant or wild-type K13. Synergy is also observed against Plasmodium berghei in vivo. We developed a detailed model of parasite responses that enables us to infer, for the first time, in vivo parasite clearance profiles from in vitro assessments of ART sensitivity. We provide evidence that the clinical marker of resistance (delayed parasite clearance) is an indirect measure of drug efficacy because of the persistence of unviable parasites with unchanged morphology in the circulation, and we suggest alternative approaches for the direct measurement of viability. Our model predicts that extending current three-day ART treatment courses to four days, or splitting the doses, will efficiently clear resistant parasite infections. This work provides a rationale for improving the detection of ART resistance in the field and for treatment strategies that can be employed in areas with ART resistance.
URI: https://hdl.handle.net/10356/79395
http://hdl.handle.net/10220/25824
ISSN: 1545-7885
DOI: 10.1371/journal.pbio.1002132
Rights: © 2015 Dogovski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SBS Journal Articles

SCOPUSTM   
Citations 10

139
checked on Sep 5, 2020

WEB OF SCIENCETM
Citations 20

137
checked on Oct 16, 2020

Page view(s) 20

349
checked on Oct 21, 2020

Download(s) 20

185
checked on Oct 21, 2020

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.